Back

Targeting Cysteine 42 in PKGIa limits diastolic dysfunction in HFpEF

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: back to basics Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jie Su

King's College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Flavin-containing monooxygenase 2 improves heart failure with preserved ejection fraction by promoting calcium-dependent nitric oxide synthesis
Professor X. Hu (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Effects of mavacamten on the cellular response to beta adrenergic and frequency dependent stress in an HFpEF mouse model
Mr N. Aliyar (Berlin, DE) Mr T. Jeising (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Deletion of the E3 ubiquitin ligase MARCH1 promotes white adipose tissue beiging and attenuates diastolic dysfunction in a multi-hit mouse model of heart failure with preserved ejection fraction
Mr H. Yang (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
From proteomics to precision: protein signatures as surrogate markers in phase II heart failure trials. A subanalysis from MYSTERY-HF
Doctor S. Braumann (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Humoral protein signature linked to circulating cell-free DNA in individuals with symptomatic heart failure
Ms E. Yapici (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: back to basics

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Beneficial effects of treatment with a soluble guanylate cyclase stimulator on cardiac function and mitochondrial activity in an animal model of early-stage HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources